Engineering a patient's own T cells to selectively target and eliminate tumour cells has cured
patients with untreatable haematologic cancers. These results have energized the field to …

Immunotherapy has emerged as an eminent and effective modality in the treatment of
cancer. However, current cancer immunotherapies lack spatial and temporal control …

The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid
tumors, and could be a promising treatment target. We report dose escalation results from …

The success of chimeric antigen receptor (CAR) T cells targeting B-cell malignancies
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …

After seeing a dramatic increase in the development and use of immunotherapy and
precision medicine over the past few decades, oncological care now embraces the start of …

The period between" successful" treatment of localized breast cancer and the onset of
distant metastasis can last many years, representing an unexploited window to eradicate …

Tumor immune microenvironment (TIME) consists of intra-tumor immunological components
and plays a significant role in tumor initiation, progression, metastasis, and response to …

Chimeric antigen receptor (CAR)-T cell therapy is one of the most promising advances in
cancer treatment. It is based on genetically modified T cells to express a CAR, which …

Cell and gene therapies hold tremendous promise for treating a range of difficult-to-treat
diseases. However, concerns over the safety and efficacy require to be further addressed in …

Cell membrane-camouflaged nanoparticles possess inherent advantages derived from their
membrane structure and surface antigens, including prolonged circulation in the …